登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600538 证券简称：国发股份 公告编号：临2026-005 北海国发川山生物股份有限公司 关于上海证券交易所对公司业绩预告相关事项问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 公司预计2025年度实现营业收入约3.3亿元，扣除与主营业务无关的业务收入和不具备商业实质的营业 收入仍为3.3亿元；归属于母公司所有者的净利润-0.85亿元。请公司补充披露：（1）根据《上海证券交 易所上市公司自律监管指南第2号一一业务办理》附件第七号《财务类退市指标：营业收入扣除》有关 规定，说明营业收入扣除相关情况，包括但不限于扣除项目、金额、相关业务开展情况及扣除原因等， 并逐项核实并说明是否存在其他应当扣除尚无扣除的情况；（2）按主要产品类别或业务板块，列示 2025年度预计实现营业收入的具体金额、占比、毛利率及同比变动情况，并说明主要影响因素；（3） 各业务板块前五大客户情况，包括客户名称、合同签订时间、合作期限、是否新增客户或关联方、销售 内容、销售金额、应 ...

内容概要：禽用疫苗是预防禽类传染病的关键生物制剂，是现代家禽养殖业疫病防控的基石。国家出台 多项政策，从全产业链构建严密监管体系，为行业筑牢质量安全防线，推动产品升级，激活市场需求。 中国作为禽类养殖与消费大国，家禽生产平稳发展，出栏量增长、存栏量优化，为禽用疫苗市场提供坚 实需求基础，催生高端疫苗市场扩容空间。禽肉产量稳健增长，拉动防疫投入，禽蛋产量调整促使精准 化免疫模式转变，共同推动禽用疫苗市场规模扩张与产品结构升级。随着畜牧业发展，兽用生物制品市 场规模扩大，2024年禽用生物制品市场复苏增长。禽用疫苗细分市场中，灭活疫苗主导，活疫苗稳基， 其他疫苗高速扩容。未来，行业将在多重驱动下高质量发展，多联多价疫苗成研发主流，新型疫苗技术 商业化加快，行业集中度提升，并向综合服务模式转型，国内企业也将加快国际化布局。 上市企业：中牧股份（600195.SH）、瑞普生物（300119.SZ）、普莱柯（603566.SH）、生物股份 （600201.SH） 相关企业：乾元浩生物股份有限公司、杭州佑本动物疫苗有限公司、金宇益康生物技术（辽宁）股份有 限公司、河南祺祥生物科技有限公司、肇庆大华农生物药品有限公司、山西 ...

Group 1: Core Insights - The company has repurchased shares amounting to 1.01% of its total share capital, with a total repurchase amount of approximately 41.87 million yuan [1][3] - The company expects a significant narrowing of its net profit loss for 2025, projecting a loss between 32 million yuan and 47 million yuan, which represents a year-on-year reduction in loss of 63.13% to 74.89% [4] - The company has obtained medical device certification in Malaysia, valid until December 2030, facilitating its expansion into overseas markets [5] Group 2: Stock Performance - The company's stock price experienced a limit-up on January 26, 2026 [2] Group 3: Business Developments - The company continues to focus on an integrated strategy of "prevention, diagnosis, and treatment," with ongoing investments in innovative pharmaceuticals and AI healthcare [5]

股票近期走势 以上内容基于公开资料整理，不构成投资建议。 财报分析 经济观察网持股5%以上股东美国联合生物医药公司(UBI)完成减持申联生物股份（600201）12,319,240 股(占公司总股本3%)，减持后持股比例从10.52%降至7.52%。减持价格区间为8.80-9.89元/股，总金额约 1.11亿元。本次减持计划自2025年11月13日启动，于2026年2月9日实施完毕，不会导致公司控股股东或 实际控制人变更。公司于2026年1月23日披露业绩预告，预计2025年归母净亏损约2000万元，较2024年 亏损收窄约55%；扣非净亏损约2350万元，收窄约51%。亏损收窄主要得益于降本增效，但动保行业竞 争加剧导致产品单价下降、应收账款减值损失增加及新车间折旧上升。 2025年业绩预亏主要反映主营业务承压：行业价格战导致销售收入和毛利率小幅下滑，同时客户回款延 迟致信用减值损失上升，新疫苗车间转固增加折旧。尽管公司通过优化销售费用及研发聚焦(如多联疫 苗进展)减亏，但自2021年起净利润已连续五年下滑，现金流压力仍存。 近7天(2026年2月5日至11日)，申联生物股价区间涨跌幅为3.63%，最高价9 ...

Core Viewpoint - Jiangsu Sihuan Biological Co., Ltd. is facing a risk of being delisted due to negative net profit and insufficient revenue as per the Shenzhen Stock Exchange regulations [2][3]. Group 1: Delisting Risk Announcement - The company announced on April 29, 2025, that its stock would be subject to delisting risk warning starting April 30, 2025, due to a negative net profit and revenue below 300 million yuan for the fiscal year 2024 [2][3]. - According to the Shenzhen Stock Exchange's listing rules, if the company continues to meet the criteria for delisting in the following fiscal year, its stock may be terminated from listing [3][11]. Group 2: Financial Performance Indicators - The audited net profit for the fiscal year 2024 was reported as negative, and the operating revenue was below 300 million yuan, triggering the delisting risk warning [3][4]. - The company projected a net profit (excluding non-recurring gains and losses) for 2025 to be between -46 million yuan and -33 million yuan, with expected operating revenue between 330 million yuan and 350 million yuan [11]. Group 3: Compliance and Disclosure Obligations - The company is required to disclose risk warning announcements every ten trading days until the annual report is released, following the initial risk warning announcement [2][11]. - The company will adhere to the information disclosure obligations as stipulated by the Shenzhen Stock Exchange, with designated media for announcements including Securities Times and China Securities Journal [11].

Core Viewpoint - The simultaneous release of refinancing optimization measures by Shanghai, Shenzhen, and Beijing stock exchanges marks a significant transformation in China's capital market, aimed at enhancing capital allocation efficiency and reshaping the A-share market landscape [1]. Group 1: Policy Framework and Differences - The policy frameworks of the three exchanges are highly similar, focusing on "supporting the strong, limiting the weak, promoting innovation, and enhancing convenience and regulation" [2]. - Shanghai Stock Exchange emphasizes "main board" characteristics, tailoring financing rules for large, mature technology companies [2]. - Shenzhen Stock Exchange adopts a bolder stance on supporting technology innovation, easing fundraising restrictions for growth-oriented enterprises [2]. - Beijing Stock Exchange focuses on "innovative small and medium-sized enterprises," addressing their financing challenges with flexible policies [2]. Group 2: Strategic Insights on Separate Announcements - The decision to release policies on the same day rather than a joint announcement reflects the nuanced wisdom of tiered regulation in China's capital market [3]. - Different market positioning allows each exchange to cater to the unique characteristics and needs of the enterprises they serve, avoiding a one-size-fits-all approach [3]. - The simultaneous release creates a strong policy resonance, reinforcing market perception of deepening capital market reforms while maintaining the distinct identities of each exchange [3]. Group 3: Deep Impacts on Market Perception - The new measures aim to shift the long-standing fear of "blood-sucking" effects of refinancing, which was believed to drain market funds and destabilize the market [4]. - The principle of "supporting the strong, limiting the weak" will act as a catalyst for market differentiation, favoring quality companies, especially in hard technology, while raising barriers for poorly performing firms [4]. - The policy directs resources towards "new productive forces," providing strong support for leading companies in sectors like semiconductors, AI, biomedicine, and high-end manufacturing [5]. - Allowing companies that have experienced stock price declines to raise funds through methods like private placements and convertible bonds offers a lifeline to solid businesses facing temporary challenges [6]. - A complete regulatory loop is established, tightening post-fundraising supervision while relaxing initial approvals, transforming refinancing from a mere "money-raising tool" to an "engine" for corporate development [7]. Group 4: Implications for Investors - The coordinated actions of the three exchanges signify the entry of China's refinancing mechanism into a "precise drip irrigation" era, providing tailored financing support for different types of enterprises [8]. - Investors are advised to focus on genuinely innovative and well-governed companies while avoiding those that merely chase trends without substance [8]. - The transformation of refinancing from a "blood-sucking machine" to a "blood-producing pump" is expected to enhance the value discovery function of the A-share market, leading to a healthier and more vibrant capital market [8].

Summary of the Conference Call for Bio Co., Ltd. Industry and Company Overview - The conference call focused on Bio Co., Ltd., specifically its developments in the African Swine Fever (ASF) vaccine sector, which is a critical area in the animal health industry. Key Points and Arguments 1. **Positive Results from ASF Vaccine Trials** Bio Co., Ltd. reported successful results from its subunit ASF vaccine attack experiment, where no deaths occurred among the immunized group under an 8,000 HAD virus attack, indicating a high protection rate. This sets a solid foundation for subsequent clinical trials and approvals [2][3]. 2. **Upcoming Clinical Trials** The company plans to conduct a second attack experiment on April 12, aiming to verify the vaccine's effectiveness throughout its lifecycle. The completion of the second clinical trial is expected by late May or early June [2][3]. 3. **Market Approval Timeline** If the results are favorable, the China National Center for Animal Health (CNCA) may participate in the review process, potentially accelerating the approval timeline. The company anticipates obtaining a temporary production license by mid to late 2026, allowing for large-scale production [2][3]. 4. **Pricing Strategy** The initial pricing for the ASF vaccine is set at 25 RMB per dose, which balances affordability for farmers and the technological uniqueness of the product. The expected gross margin is projected to exceed 50%, indicating strong profitability potential [2][5]. 5. **Competitive Advantages** Bio Co., Ltd. is currently the only company certified by the Chinese Academy of Sciences to conduct clinical trials for the ASF vaccine, providing a significant competitive edge. The involvement of CNCA in the process is expected to expedite market entry [2][6][7]. 6. **Collaboration in Vietnam** The company is collaborating with local firms in Vietnam to promote the ASF vaccine, addressing the issue of local pig populations infected with recombinant viruses. They expect to obtain production licenses within six months and begin sales within 18 months [2][9]. 7. **Future Developments in mRNA Vaccines** Bio Co., Ltd. is also working on an mRNA vaccine for feline infectious peritonitis, projected to be launched domestically by 2028. The company is collaborating with two major U.S. pharmaceutical companies, utilizing a revenue-sharing model that could yield significant returns [3][10]. 8. **Overall Business Outlook for 2026** The company anticipates explosive growth in the ruminant service sector in 2026, driven by the ASF vaccine's market entry. The poultry business remains stable, and overall, the company expects positive trends across its various segments [3][12]. Additional Important Information - The company is currently focusing on testing the vaccine primarily for piglets, with plans for further discussions regarding its application for sows based on feedback from breeding farms [5]. - The competitive landscape includes other companies like Jinyu Biological, which has completed clinical trials but may face delays in large-scale production due to additional trial requirements [8]. - The fourth quarter's specific data on other products like swine foot-and-mouth disease vaccines is pending, but the ASF vaccine is expected to drive sales of existing products [11].

（编辑 丛可心） 证券日报网讯 2月6日，生物股份发布公告称，公司已完成注册资本的工商变更登记，注册资本变更为 壹拾壹亿壹仟壹佰柒拾肆万柒仟捌佰贰拾陆元（人民币），并换领呼和浩特市市场监督管理局新《营业 执照》。 ...

证券代码：600201 证券简称：生物股份 公告编号：临2026-004 金宇生物技术股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 类型：股份有限公司（上市、自然人投资或控股） 住所：内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金宇大街 1 号 法定代表人：张翀宇 注册资本：壹拾壹亿壹仟壹佰柒拾肆万柒仟捌佰贰拾陆元（人民币元） 成立日期：1993 年 03 月 13 日 经营范围：兽用生物药品制造和销售；兽用化学药品制剂制造和销售；化学 试剂和助剂制造和销售；生物药品制剂制造和销售；生物技术开发、转让、咨询 服务；先进医疗设备及器械制造和销售；货物进出口、技术进出口；物业管理。 特此公告。 金宇生物技术股份有限公司（以下简称"公司"）第十一届董事会第十八次 会议和 2024 年年度股东大会审议通过了《关于修订<公司章程>及其他制度的议案》， 具体内容详见公司披露在上海证券交易所网站的《金宇生物技术股份有限公司关 于修订<公司章程>及其他制度的公告》（公告编号：临 2025-02 ...

Core Viewpoint - The actual controller of Baolingbao Biotech Co., Ltd., Mr. Dai Sichong, has expanded the shareholding plan to include a new entity, CEDARWALK BIOTECH HONG KONG LIMITED, to facilitate the acquisition of shares in the company [1][2]. Summary by Sections Shareholding Plan Overview - The original plan was to increase shareholding by 18,488,369 shares (5% of total shares) to a maximum of 36,976,738 shares (10% of total shares) starting from October 8, 2024, for a period of six months [1]. - The plan has been extended by 12 months, now set to conclude on April 7, 2026, while other details remain unchanged [2]. Addition of New Entity - CEDARWALK BIOTECH HONG KONG LIMITED has been added as a new entity to the shareholding plan, which is controlled by Mr. Dai Sichong [2][3]. - This entity will operate through a specific investment account managed by Guotou Securities Asset Management (Hong Kong) [2]. Shareholding Changes - As of February 4, 2026, the cumulative shares acquired by Shenzhen Songjing Investment Partnership and CEDARWALK BIOTECH HONG KONG LIMITED amount to 6,375,700 shares, representing 1.67531% of the total shares [3]. - The total shares acquired from November 2025 to February 2026 reached 5,076,300 shares, increasing the combined holding to 13.99607% [4]. Compliance and Commitments - The shareholding plan complies with relevant laws and regulations, ensuring that it does not affect the company's listing status or control [6]. - CEDARWALK BIOTECH HONG KONG LIMITED has committed to not reducing its holdings for six months post-acquisition [6].